UNICREDIT BANK/CALL/NOVO-NORDISK B/850/0.2/18.12.24 | Market Closed - BOERSE MUENCHEN 01:15:51 01/06/2024 am IST | ||
| 3.64 EUR | +1.11% |
|
| 1 month | +5.20% | ||
| 3 months | +54.24% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
| Date | Price | Change |
|---|---|---|
| 31/24/31 | 3.64 | +1.11% |
| 30/24/30 | 3.6 | +3.45% |
| 29/24/29 | 3.48 | -2.25% |
| 28/24/28 | 3.56 | -2.47% |
| 27/24/27 | 3.65 | -8.06% |
Real-time BOERSE MUENCHEN
Last update May 01, 2024 at 01:15 am IST
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
UniCredit
|
| WKN | HC7Y7U |
| ISIN | DE000HC7Y7U3 |
| Date issued | 10/07/2023 |
| Strike | 850 kr |
| Maturity | 18/12/2024 (199 Days) |
| Parity | 5 : 1 |
| Emission price | 0.47 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 4.3 € |
|---|---|
| Lowest since issue | 0.33 € |
| Spread | 0.12 € |
| Spread % | 3.17% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
927.3
DKK
Average target price
917.2
DKK
Spread / Average Target
-1.09%
- Stock Market
- Warrants
- Warrant
